All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

How to optimize donor selection for allogeneic transplant?

Featured
Jul 7, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in GvHD.

During the EHA 2022 Congress, the GvHD Hub was pleased to speak to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How do you optimize donor selection for allogeneic transplant? Comparing MSD, UD, and haploidentical donors.

How to optimize donor selection for allogeneic transplant?

Nagler begins by comparing leukemia-free and relapse-free survival with different donor types, including sibling, unrelated, mismatched, and haploidentical donors. Nagler goes on to talk about incidence of chronic GvHD (cGvHD) in transplant, and factors to consider when selecting a donor. Finally, Nagler discusses how to prevent GvHD and infections.